Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Sep 15, 2025; 17(9): 103702
Published online Sep 15, 2025. doi: 10.4251/wjgo.v17.i9.103702
Published online Sep 15, 2025. doi: 10.4251/wjgo.v17.i9.103702
Utility of inflammatory markers as predictors of recurrence in gastrointestinal stromal tumors: Insights from a nomogram-based approach
Chris B Lamprecht, Tyler Kashuv, Brandon Lucke-Wold, Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL 32610, United States
Author contributions: Lamprecht CB and Kashuv T contributed to the literature research, manuscript composition and revision; Lucke-Wold B contributed to conceptualization and revision of the manuscript.
Conflict-of-interest statement: There are no conflicts of interest to disclose for all authors.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Brandon Lucke-Wold, MD, PhD, Lillian S. Wells Department of Neurosurgery, University of Florida, 1505 SW Archer Rd, Gainesville, FL 32608, United States. brandon.lucke-wold@neurosurgery.ufl.edu
Received: November 28, 2024
Revised: April 3, 2025
Accepted: April 21, 2025
Published online: September 15, 2025
Processing time: 291 Days and 14.9 Hours
Revised: April 3, 2025
Accepted: April 21, 2025
Published online: September 15, 2025
Processing time: 291 Days and 14.9 Hours
Core Tip
Core Tip: Gastrointestinal stromal tumor (GIST) treatment is complicated due to its high recurrence rate and multifactorial etiology. This editorial explores the findings of a recent study that evaluates the impact of inflammatory markers on GIST tumor progression and prognosis. Platelet/lymphocyte ratio and monocyte/lymphocyte ratio significantly correlated with recurrence-free survival of patients with GISTs. This editorial explores how future integration of genetic mutations, tumor staging, and molecular profiling could bolster these results and future predictive models developed from this analysis.